Scientific split - the human genome breakthrough dividing former colleagues

Two groups are racing to establish scientific and commercial priority over the discovery of the decade

Science Editor

The money men have moved in on a new technique for editing the human genome that promises to revolutionise the way many human diseases will be treated in the future. But Big Money has in the process divided a scientific community into two competing camps.

Some might see it has healthy scientific rivalry spilling over into commercial competition which could ultimately speed up medical innovation. But behind closed doors there is a desperate race to establish scientific and commercial priority over what could be the scientific discovery – and intellectual property – of the decade.

On the one side is a consortium of world-class researchers led by French-born Professor Emmanuelle Charpentier who made a key discovery behind the Crispr gene editing technique and has been promised $25m (£16m) by a group of venture capitalists to commercialise her invention for medical use.

On the other side is her former colleague and the co-discoverer of the gene-editing process, Professor Jennifer Doudna of the University of California, Berkeley, who has joined a rival consortium of researchers with $43m in venture capital to advance the Crispr technique into the clinic.

Each group has recruited a formidable panel of senior scientists as advisers. The Charpentier team, called Crispr Therapeutics, includes Nobel Laureate Craig Mello, the co-discoverer of a gene-silencing technique known as RNAi, and Daniel Anderson of the Massachusetts Institute of Technology, who was the first person to show that Crispr can cure a genetic disease in an adult animal.

Meanwhile the Doudna team, known as Editas Medicine, includes the Harvard geneticist George Church, a pioneer in synthetic biology, and Feng Zhang of MIT and the Broad Institute, who successfully managed to get Crispr to work in human cells and was this month awarded the first US patent on the technique – much to the dismay of Professor Charpentier.

“I have to be careful what I say here. It is very surprising. But the fundamental discovery comes from my laboratory and no-one has told me that they have scooped me,” Professor Charpentier told The Independent.

“Be certain that this discovery did not happen only by chance. I have been thinking, defending and carrying this study from Austria to Sweden and now Germany,” she said.

Patent attorneys are now pouring over the rival patent applications, in particular the claims relating to who has priority over a key element of the Crispr technique called Cas9, a bacterial gene for an enzyme that snips both strands of the DNA double helix at the same place – a key feature of the gene-editing process.

Professor Charpentier said that she identified Cas9, the most important fundamental discovery behind Crispr (pronounced “crisper”), when she worked at Umea University in Sweden, before she had teamed up with Professor Doudna to co-author a scientific paper on Crispr-Cas9 published in August 2012 in the journal Science.

Professor Charpentier, who is now at the Hannover Medical School in Germany, said that Cas9 was in fact described for the first time in an earlier scientific paper, published in Nature in March 2011, under its former name of Csn1, which she had isolated from the bacterium Steptococcus pyogenes.

“I was the scientist who described the technology and I kept the intellectual property when I was in Sweden….Editas does not have access to the intellectual property of the patent where I’m the co-inventor,” Professor Charpentier said.

“I made the decision to do something in Europe and I made the decision not to do something with Editas Medicine. I’m trying to remain true to myself….The aim is to use Crispr-Cas9 as a kind of genetic medicine to treat serious diseases. The point about Cas9 is that it works in every cell and in every organism tested – it’s mind blowing,” she said.

For her part, Professor Doudna said there is room for both camps to develop new medical therapies based on Crispr-Cas9.

“Emmanuelle and I are excited to see this platform employed to help patients, and there are of course many different targets and strategies to be taken, providing opportunities for multiple companies in this space,” Professor Doudna said.

“In addition to start-ups, many existing companies are also interested in using the technology for various applications that extend beyond human therapeutics. I expect that the commercial landscape will continue to evolve as the technology matures,” she said.

The main barrier to using Crispr-Cas9, however, will be its safe and efficient delivery to the cells and tissues that need the genetic therapy. Professor Mello believes that the first treatments are likely to involve the genetic manipulation of stem cells in the laboratory, before transplantation back into the affected parts of the body.

“Delivery to cells within the context of the whole body, brain or other organ is very difficult and inefficient… This is why Crispr therapies will no doubt be limited for the foreseeable future to applications where stem cells can be modified one, or a few, at a time and then reintroduced after double checking that only the intended change was made,” Professor Mello said.

WHAT IS CRISPR?

The human genome consists of a long sequence of "letters" written in the code of the genetic alphabet - the three billion base-pairs of the DNA molecule. The gene-editing technique known as Crispr-Cas9 is able for the first time to delete or swap any of these letters, right down to changing a single base pair at any designated place in the genome.

Crispr, which stands for clustered regularly interspaced short palindromic repeats, was originally discovered as a kind of immune system in bacteria to defend against invading viruses. Its potential for editing the genomes of animals, including humans, only came with the discovery of the Cas9 gene, an enzyme for cutting both strands of DNA, found in the bacterium Streptococcus pyogenes.

The commercial applications of Crispr, which could extend to treating genetic diseases and cancer, will depend to a great extent on Cas9 and who owns the intellectual property on this part of the invention. This is why patent disputes are likely to focus on who did what and when in terms of the Cas9 discovery. Emmanuelle Charpentier of Hannover Medical School in Germany and Jennifer Doudna of the University of California, Berkeley are both named as co-inventors on one patent.

 

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
Buttoned up: Ryan Reynolds with Helen Mirren in ‘Woman in Gold’
filmFor every box-office smash in his Hollywood career, there's always been a misconceived let-down. Now he says it's time for a reboot
News
people
News
Actress Julianne Moore wins the Best Actress in a Leading Role Award for 'Still Alice' during the 87th Annual Academy Awards in Hollywood, California
people
Sport
Ross Barkley
footballPaul Scholes says it's time for the Everton playmaker to step up and seize the England No 10 shirt
News
'We will fix it': mice in the 1970s children’s programme Bagpuss
science
Life and Style
2 Karl Lagerfeld and Choupette
fashion
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Recruitment Genius: Customer Service Executive

£18000 - £22000 per annum: Recruitment Genius: This is an exciting opportunity...

Recruitment Genius: Retail Buyer / Ecommerce Buyer

£30000 - £35000 per annum: Recruitment Genius: Working closely with the market...

Recruitment Genius: Sales Executive - CAD Software Solutions Sales

£20000 - £50000 per annum: Recruitment Genius: A reputable company, famed for ...

Ashdown Group: Client Accountant Team Manager - Reading

Negotiable: Ashdown Group: The Ashdown Group has been engaged by a highly resp...

Day In a Page

War with Isis: Iraq declares victory in the battle for Tikrit - but militants make make ominous advances in neighbouring Syria's capital

War with Isis

Iraq declares victory in the battle for Tikrit - but militants make make ominous advances in neighbouring Syria
Scientists develop mechanical spring-loaded leg brace to improve walking

A spring in your step?

Scientists develop mechanical leg brace to help take a load off
Peter Ackroyd on Alfred Hitchcock: How London shaped the director's art and obsessions

Peter Ackroyd on Alfred Hitchcock

Ackroyd has devoted his literary career to chronicling the capital and its characters. He tells John Walsh why he chose the master of suspense as his latest subject
Ryan Reynolds interview: The actor is branching out with Nazi art-theft drama Woman in Gold

Ryan Reynolds branches out in Woman in Gold

For every box-office smash in Ryan Reynolds' Hollywood career, there's always been a misconceived let-down. It's time for a rethink and a reboot, the actor tells James Mottram
Why Robin Williams safeguarded himself against a morbid trend in advertising

Stars safeguard against morbid advertising

As film-makers and advertisers make increasing posthumous use of celebrities' images, some stars are finding new ways of ensuring that they rest in peace
The UK horticulture industry is facing a skills crisis - but Great Dixter aims to change all that

UK horticulture industry facing skills crisis

Great Dixter manor house in East Sussex is encouraging people to work in the industry by offering three scholarships a year to students, as well as generous placements
Hack Circus aims to turn the rule-abiding approach of TED talks on its head

Hack Circus: Technology, art and learning

Hack Circus aims to turn the rule-abiding approach of TED talks on its head. Rhodri Marsden meets mistress of ceremonies Leila Johnston
Sevenoaks is split over much-delayed decision on controversial grammar school annexe

Sevenoaks split over grammar school annexe

If Weald of Kent Grammar School is given the go-ahead for an annexe in leafy Sevenoaks, it will be the first selective state school to open in 50 years
10 best compact cameras

A look through the lens: 10 best compact cameras

If your smartphone won’t quite cut it, it’s time to invest in a new portable gadget
Paul Scholes column: Ross Barkley played well against Italy but he must build on that. His time to step up and seize that England No 10 shirt is now

Paul Scholes column

Ross Barkley played well against Italy but he must build on that. His time to step up and seize that England No 10 shirt is now
Why Michael Carrick is still proving an enigma for England

Why Carrick is still proving an enigma for England

Manchester United's talented midfielder has played international football for almost 14 years yet, frustratingly, has won only 32 caps, says Sam Wallace
Tracey Neville: The netball coach who is just as busy as her brothers, Gary and Phil

Tracey Neville is just as busy as her brothers, Gary and Phil

The former player on how she is finding time to coach both Manchester Thunder in the Superleague and England in this year's World Cup
General Election 2015: The masterminds behind the scenes

The masterminds behind the election

How do you get your party leader to embrace a message and then stick to it? By employing these people
Machine Gun America: The amusement park where teenagers go to shoot a huge range of automatic weapons

Machine Gun America

The amusement park where teenagers go to shoot a huge range of automatic weapons
The ethics of pet food: Why are we are so selective in how we show animals our love?

The ethics of pet food

Why are we are so selective in how we show animals our love?